罗氏集团（Roche）2025年Q1罗氏集团制药管线更新报告（英文版）（80页）.pdf

1、Roche Group development pipelineMarketed products development programmesRoche Pharma global development programmesRoche Pharma research and early development(pRED)Genentech research and early development(gRED)Changes to the development pipelineQ1 2025 update2New to phase IINew to phase IIINew to reg

2、istrationRemoved from phase IRemoved from phase IIRemoved from phase IIIApprovalsNew to phase I2 NMEs:RG6662 HTT miRNA GT(SPK-10001)Huntingtons diseaseCHU MINT91-solid tumors1 AI:RG6631afimkibart(anti-TL1A)-MASH2 NMEs:RG6315 NME-fibrosisRGXXXX P-MUC1C-ALLO1-solid tumors Status as of April 24,20252 A

3、Is(US):RG6321 Susvimo DMERG3625 TNKase stroke1 AI(EU):RG6026 Columvi+chemo-2L+DLBCL2 AIs:RG6631 afimkibart(anti-TL1A)-Crohns diseaseRG6114 Itovebi+CDK4/6i+letrozole-1L ES PIK3CA-mut.HR+HER2-advanced BC2 NMEs:RG6351 anti-Tie2 agonist-retinal diseaseRG6287 NME-immunology 2 AIs:RG6631 afimkibart(anti-T

4、L1A)atopic dermatitisRG6168 Enspryng-DMD1 AI:RG6058 tiragolumab+T-locally advanced esophageal cancerRoche Group development pipeline3Status as of April 24,2025RG6026Columvi monotherapy+combosheme tumorsRG6076englumafuspalfa combosheme tumorsRG6114Itovebisolid tumorsRG6160cevostamabr/r multiplemyelom

5、aRG6171giredestrant monotherapy+combos solid tumors RG6221 LTBR agonistsolid tumorsRG6279eciskafusp alfa Tsolid tumorsRG6330divarasib monotherapy+combos solid tumorsRG6344mosperafenib(BRAF inhibitor(3)solid tumorsRG6411-solid tumorsRG6440anti-latent TGF-1(SOF10)solid tumorsRG6457WRN covalent inhibit

6、or solid tumorsRG6468-solid tumorsRG6537AR degradermCRPCRG65381P-BCMA-ALLO1r/r multiplemyelomaRG65401P-CD19 x CD20-ALLO1heme tumors RG6561-solid tumorsRG65962HER2 TKIHER2+BCRG6614USP1 inhibitorsolid tumorsRG6620KRAS G12D inhibitorsolid tumorsRG66483cMET ADCsolid tumorsRG7828Lunsumio monotherapy+comb